---
figid: PMC5000709__ijms-17-01312-g003
figtitle: Kallistatin inhibits Wnt canonical pathway induced angiogenesis and inflammation
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Bos taurus
- Gallus gallus
- Lareunionomyces loeiensis
pmcid: PMC5000709
filename: ijms-17-01312-g003.jpg
figlink: /pmc/articles/PMC5000709/figure/ijms-17-01312-f003/
number: F3
caption: 'Kallistatin inhibits Wnt canonical pathway induced angiogenesis and inflammation.
  In the Wnt canonical pathways, mostly mediated by Wnt1, 3, 3a, 7a and 7b, Wnt/Fzd
  binding phosphorylates the associated co-receptor LRP5/6. This recruits Dsh which
  leads to binding of Axin at the membrane. Axin forms a degradation complex with
  APC, CK1α and GSK3β for β-catenin degradation. The recruitment binding of Axin to
  the membrane caused by Wnt/Fzd leads to an inactive degradation complex and the
  accumulation of β-catenin. The accumulated β-catenin mediates Wnt signaling by activating
  transcription factors, such as TCF, which induces transcription of genes, such as
  VEGF, ICAM-1 and TNF-α. Kallistatin binds to LRP6 and prevents LRP6 from phosphorylation
  which results in β-catenin degradation. Without β-catenin, Wnt canonical signaling
  is blocked. Abbreviation: AP-1—activator protein-1; APC—adenomatous polyposis coli;
  CAMKII—calmodulin dependent protein kinase; CK1α—casein kinase 1α; Dsh—the protein
  disheveled; GSK3β—glycogen synthase kinase-3β; ICAM-1—intracellulcar adhesion molecule-1;
  LRP5/6—low density lipoprotein receptor-related protein 5 or 6; PCP—planar cell
  polarity; OPG—osteoprotegerin; OPN—osteopontin; TCF—T-cell factor; TNF-α—tumor necrosis
  factor alpha; VEGF—vascular endothelial growth factor; the red arrow indicates increase
  in level; the tubular structure on the left represents cytoskeleton. The blue arrow
  lines indicate promotional activity; the red stop lines indicate inhibiting activity;
  the red dashed cross indicates degradation.'
papertitle: The Potential Role of Kallistatin in the Development of Abdominal Aortic
  Aneurysm.
reftext: Jiaze Li, et al. Int J Mol Sci. 2016 Aug;17(8):1312.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9596461
figid_alias: PMC5000709__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Bos taurus
- Gallus gallus
redirect_from: /figures/PMC5000709__F3
ndex: c744d9a2-dee0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5000709__ijms-17-01312-g003.html
  '@type': Dataset
  description: 'Kallistatin inhibits Wnt canonical pathway induced angiogenesis and
    inflammation. In the Wnt canonical pathways, mostly mediated by Wnt1, 3, 3a, 7a
    and 7b, Wnt/Fzd binding phosphorylates the associated co-receptor LRP5/6. This
    recruits Dsh which leads to binding of Axin at the membrane. Axin forms a degradation
    complex with APC, CK1α and GSK3β for β-catenin degradation. The recruitment binding
    of Axin to the membrane caused by Wnt/Fzd leads to an inactive degradation complex
    and the accumulation of β-catenin. The accumulated β-catenin mediates Wnt signaling
    by activating transcription factors, such as TCF, which induces transcription
    of genes, such as VEGF, ICAM-1 and TNF-α. Kallistatin binds to LRP6 and prevents
    LRP6 from phosphorylation which results in β-catenin degradation. Without β-catenin,
    Wnt canonical signaling is blocked. Abbreviation: AP-1—activator protein-1; APC—adenomatous
    polyposis coli; CAMKII—calmodulin dependent protein kinase; CK1α—casein kinase
    1α; Dsh—the protein disheveled; GSK3β—glycogen synthase kinase-3β; ICAM-1—intracellulcar
    adhesion molecule-1; LRP5/6—low density lipoprotein receptor-related protein 5
    or 6; PCP—planar cell polarity; OPG—osteoprotegerin; OPN—osteopontin; TCF—T-cell
    factor; TNF-α—tumor necrosis factor alpha; VEGF—vascular endothelial growth factor;
    the red arrow indicates increase in level; the tubular structure on the left represents
    cytoskeleton. The blue arrow lines indicate promotional activity; the red stop
    lines indicate inhibiting activity; the red dashed cross indicates degradation.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SERPINA4
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - RAC1
  - RNASE1
  - CDC42
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - CTNNB1
  - CALM1
  - CALM2
  - CALM3
  - KRIT1
  - CAMKMT
  - MAPK8
  - MAPK9
  - MAPK10
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - GSK3B
  - HNF4A
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - NIN
  - SPP1
  - BTF3P11
  - TNFRSF11B
  - LRP6
  - LRP5
  - Rac1
  - Cdc42
  - Hspg2
  - Ctnnb1
  - Calm1
  - Tmem50a
  - Mapk8
  - Gm12892
  - Gsk3b
  - Prrx1
  - Jun
  - Nin
  - Spp1
  - Tnfrsf11b
  - Lrp6
  - Lrp5
  - Wnt2
  - Rnase1l1
  - Calm2
  - Csnk1a1
  - Prkcg
  - GSK3A
  - Cancer
---
